Coyne Terrance P. 4

What Happened

• Terrance P. Coyne, Executive Vice President & Chief Financial Officer of Royalty Pharma (RPRX), sold 64,399 Class A ordinary shares on May 26, 2026. The weighted-average price was $53.98 per share, for total proceeds of approximately $3,476,116. This was a sale (not a purchase) and appears to have been executed under a pre-established plan.

Key Details

• Transaction date: May 26, 2026; Form 4 filed May 28, 2026 (timely).
• Price: weighted average $53.98; shares were sold in multiple trades at prices ranging from $53.64 to $54.63 (footnote offers breakdown on request).
• Total proceeds: ~$3.48 million.
• Plan: Transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on February 24, 2026 (footnote F1).
• Shares owned after transaction: not specified in the provided filing table. The filing’s remarks note the reporting person and family vehicles hold exchangeable interests equal to 6,448,180 Class A shares (via RPI US Partners 2019, LP) and 1,807,277 Class A-equivalent shares (via Class E RPH shares, which are subject to vesting).
• Filing timeliness: filing covers the May 26 trade and was submitted on May 28 — no late filing indicated.

Context

• The sale was executed under a 10b5-1 plan, which means it was likely pre-arranged and scheduled; such sales are often routine and do not, by themselves, indicate management’s view of the company’s prospects. The reporting person also holds substantial exchangeable interests that could convert into additional Class A shares (not necessarily currently owned or vested).